Clinical Trials Sponsored by lurye Clinic

Total 19697 results

Dinara Zhumanbayeva

Unknown

The Impact of Air Travel on Passenger Cognitive Functions

Air Travel
Geisinger Clinic
Clinical Innovations

Withdrawn

The Effect of Traxi Panniculus Retractor on Surgical Time at Non-emergent Cesarean Delivery in Obese Women

Obesity

United States
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
Luye Pharma Group Ltd.

Recruiting

First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.

Advanced Solid Tumor

China
Luye Pharma Group Ltd.

Recruiting

A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.

Generalized Anxiety Disorder

China
Luye Pharma Group Ltd.

Recruiting

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Bone Metastases From Solid Tumors

China
Luye Pharma Group Ltd.

Enrolling by invitation

Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD

Parkinson Disease

China
Luye Pharma Group Ltd.

Completed

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

Breast Cancer

China
Luye Pharma Group Ltd.

Completed

Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors

Advanced Solid Tumor

China
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

China
Luye Pharma Group Ltd.

Completed

A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients

Parkinson Disease

China
Luye Pharma Group Ltd.

Completed

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

Parkinson Disease

United States
Luye Pharma Group Ltd.

Completed

A Relative Bioavailability Food Effect Study of LY03005

Major Depressive Disorder

United States
Luye Pharma Group Ltd.

Completed

A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer

Cancer of Prostate

United States
Luye Pharma Group Ltd.

Completed

A Study of LY03005 vs Pristiq

Major Depressive Disorder

United States
Luye Pharma Group Ltd.

Completed

Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease

Parkinson Disease

United States
Luye Pharma Group Ltd.

Unknown

A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer Recurrent

China
Luye Pharma Group Ltd.

Completed

Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers

Lipid Metabolism Disorder

United States
Luye Pharma Group Ltd.

Completed

Safety, Tolerability and Pharmacokinetics Study of LY03005 (LY03005SAD)

Major Depressive Disorder

United States
Luye Pharma Group Ltd.

Completed

Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder (LY03004SAD)

Schizophrenia | Schizoaffective Disorder

United States
Embryolab Fertility Clinic
ART Fertility Clinics LLC

Recruiting

The Effect of Dual Trigger (GnRH Agonist + hCG) for Final Maturation in Oocyte Donors With History of a Previous Cycle With Suboptimal Response to GnRH Agonist Only Trigger

Ovarian Stimulation | Oocyte Donors | Human Chorionic Gonadotropin

Greece
Luye Pharma Group Ltd.

Recruiting

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects

Tardive Dyskinesia | Huntington Disease

China
Luye Pharma Group Ltd.

Not yet recruiting

Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg

Prostate Cancer

China
Luye Pharma Group Ltd.

Active, not recruiting

Comparative Efficacy, Safety, PK, and Immunogenicity Study

Osteoporosis, Postmenopausal

Poland, United States, Czechia, Bulgaria, Japan
Luye Pharma Group Ltd.

Completed

Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer

Small Cell Lung Cancer

China
Luye Pharma Group Ltd.

Completed

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

Tardive Dyskinesia | Huntington Disease

China
Luye Pharma Group Ltd.

Completed

Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer

Advanced Breast Cancer

China
Luye Pharma Group Ltd.

Completed

A Dose-escalation Study of LPM3480392 in Chinese Healthy Subjects

Healthy

China
Luye Pharma Group Ltd.

Completed

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Prostate Cancer

China
Luye Pharma Group Ltd.

Completed

An Exploratory Study of LPM3480392 at Different Infusion Rates in Chinese Healthy Subjects

Healthy

China
Luye Pharma Group Ltd.

Enrolling by invitation

to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers

Parkinson's Disease

Australia
Luye Pharma Group Ltd.

Completed

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

Parkinson Disease

United States
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003

Parkinson Disease
Luye Pharma Group Ltd.

Completed

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

Schizophrenia | Schizoaffective Disorder | Schizo Affective Disorder

United States
Luye Pharma Group Ltd.

Completed

Pilot BA Study of New LY03005 vs Pristiq

Major Depression

United States
Luye Pharma Group Ltd.

Completed

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

Parkinson's Disease

United States
Luye Pharma Group Ltd.

Completed

Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005

Major Depressive Disorder, Recurrent, Unspecified

United States
Luye Pharma Group Ltd.

Completed

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease (03003MAD)

Parkinson's Disease

United States
Luye Pharma Group Ltd.

Completed

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States
Luye Pharma Group Ltd.

Completed

Bioavailability of LY03004 and Risperdal® Consta®

Schizophrenia | Schizoaffective Disorder

United States
Luye Pharma Group Ltd.

Recruiting

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

Relapsed Small Cell Lung Cancer

China
Luye Pharma Group Ltd.

Recruiting

Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients

Advanced Solid Tumor

China
Luye Pharma Group Ltd.

Completed

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Mental Disorders | Psychotic Disorders | Mood Disorders | Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders | Molecular Mechanisms of Pharmacological Action | Tranquilizing Agents | Physiological Effects of Drugs | Psychotropic Drugs | Antipsychotic Agents | Neurotransmitter Agents | Central...

United States
Luye Pharma Group Ltd.

Completed

Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Abdominal Surgery

Pain, Postoperative

China
Luye Pharma Group Ltd.

Completed

Relative Bioavailability of LY03010 Compared to Listed Drug

Mental Disorders | Psychotic Disorders | Mood Disorders | Schizophrenia | Molecular Mechanisms of Pharmacological Action | Tranquilizing Agents | Physiological Effects of Drugs | Psychotropic Drugs | Antipsychotic Agents | Central Nervous System Depressants | Neurotransmitter Agents | Schizophrenia Spectrum

United States
Luye Pharma Group Ltd.

Completed

Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Prostate Cancer

China
Luye Pharma Group Ltd.

Completed

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

Major Depressive Disorder

United States
Mayo Clinic
Mayo Clinic Clinic Center for Innovation; Mayo Clinic Center for Clinical and...

Completed

Cardiovascular Health Promotion Among African-Americans by FAITH! (FAITH!)

Cardiovascular Diseases | Smoking Cessation | Hypertension | Obesity | Diabetes | Physical Activity | Diet Modification | Pre Diabetes | Prevention | High Cholesterol
Eduardo N. Chini

Recruiting

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

Mitochondrial Myopathy

United States

3

Subscribe